1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 80
Sponsor: Other
Protocol IDs: A-39/29.1.2007, ICMR No-5/8/7/26/99-ECD-I, NCT00522405
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: RFA005, NCT00728078
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: CAN-NCIC-MY10, NCT00049673, NCIC-MY.10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, MY10
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: T2202, NCT00225290
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C05009, NCT00507416
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: UARK 2006-66, NCT00572169
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: 2006-15, NCT00574080
|
|
11.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1A06, E1A06, NCT00602641
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25009, 59306670 7R01CA115399, NCT00670631
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-020, NCT00689936
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NMSG 17/07, EudraCT no. 2007-001292-11, NCT00602511
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MHOPES-myeloma09, NCT00892346
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: LCI-THALIDOMIDE, LCI-09-06-15, NCT00921531
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TMSG-2005-001, NCT00934154
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: RPCI-RPC-0112, CELGENE-RPCI-RPC-0112, NCT00096018
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: CHNMC-04064, NCT00112827
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: 931003, NCT00155272
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MM2005, NCT00406978
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0595, NCT00527657
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0179, NCT00966693
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: ICRF-96.084, EU-99018, NCT00004876
|
